(NYSE: ABBV) Abbvie's forecast annual revenue growth rate of 8.37% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.72%.
Abbvie's revenue in 2026 is $62,819,000,000.On average, 35 Wall Street analysts forecast ABBV's revenue for 2026 to be $121,209,054,691,884, with the lowest ABBV revenue forecast at $113,597,711,219,016, and the highest ABBV revenue forecast at $125,544,764,274,618. On average, 35 Wall Street analysts forecast ABBV's revenue for 2027 to be $131,258,572,257,732, with the lowest ABBV revenue forecast at $122,277,964,348,589, and the highest ABBV revenue forecast at $140,168,508,454,035.
In 2028, ABBV is forecast to generate $141,262,153,210,234 in revenue, with the lowest revenue forecast at $129,118,986,151,501 and the highest revenue forecast at $152,652,666,527,221.